| Overview |
| bsm-61024r |
| Dystrophin Recombinant Antibody |
| IHC-P, IHC-F, IF |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Dystrophin |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at 4°C for short term. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. |
| Target |
| 1756 |
| P11532 |
| Cytoplasm, Cell membrane |
| Alternative namesApo dystrophin; BMD; CMD3B; DMD; DMD_HUMAN; Duchenne muscular dystrophy protein; DXS142; DXS164; DXS206; DXS230; DXS239; DXS268; DXS269; DXS270; DXS272; Dystrophin; Muscular dystrophy Duchenne and Becker types. |
| Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission. |
| Application Dilution |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF |
|